Home Heart and Cardiovascular Health Aspirin for Heart Prevention: Who Should Take It and Who Shouldn’t

Aspirin for Heart Prevention: Who Should Take It and Who Shouldn’t

3
Aspirin can prevent some cardiovascular events but also causes bleeding. Learn who may benefit, who should not start it, and why prior heart disease changes the answer.

Daily low-dose aspirin can prevent some heart attacks and ischemic strokes, but it also increases the risk of major bleeding. That tradeoff is why aspirin is no longer recommended routinely for most adults who have never had cardiovascular disease. For primary prevention, the U.S. Preventive Services Task Force says adults ages 40–59 with at least a 10% estimated 10-year cardiovascular risk should make an individual decision with a clinician, and it recommends against starting aspirin at age 60 or older for primary prevention. The situation is different for secondary prevention: people with established coronary artery disease, a prior heart attack, certain strokes, or a coronary stent may be advised to take antiplatelet therapy because the benefit is usually larger. Aspirin is not appropriate for everyone, especially people with active bleeding, a history of some gastrointestinal bleeds, aspirin allergy, or high bleeding risk. Do not start or stop long-term aspirin solely from an online risk estimate; the reason you take it matters.

Table of Contents

Primary vs. secondary prevention

The most important aspirin question is not “Is aspirin good for the heart?” It is whether you already have established cardiovascular disease.

Primary prevention means trying to prevent a first heart attack or ischemic stroke in someone who has not been diagnosed with atherosclerotic cardiovascular disease. In this setting, aspirin can reduce clot-related events a little, but it can also cause gastrointestinal bleeding and bleeding in the brain. Because modern treatment of cholesterol, blood pressure, and smoking has lowered baseline cardiovascular risk, aspirin’s absolute benefit is smaller for many people than it was decades ago.

Secondary prevention means preventing another event in someone who already has atherosclerotic cardiovascular disease, such as a previous heart attack or established coronary artery disease. In this setting, antiplatelet therapy has a much clearer role because the risk of another clot-related event is higher.

This distinction explains why advice that sounds contradictory can both be correct. “Do not start aspirin routinely at age 65” may be appropriate for a healthy adult with no cardiovascular disease, while “continue aspirin” may be correct for a 65-year-old with prior myocardial infarction.

Aspirin works by irreversibly inhibiting platelet cyclooxygenase-1, reducing thromboxane A2 and making platelets less likely to form a clot. That effect lasts for the life of the platelet. It is useful when a clot forming on a ruptured atherosclerotic plaque is a major threat, but the same antiplatelet effect makes bleeding harder to stop.

Who might consider aspirin

For adults without known cardiovascular disease, aspirin is now a selective option rather than a routine recommendation.

The 2022 U.S. Preventive Services Task Force recommendation applies to adults without known cardiovascular disease who are not at increased bleeding risk. For people 40–59 years old with a 10% or greater 10-year cardiovascular disease risk, starting low-dose aspirin should be an individual decision. The expected net benefit is small.

That means cardiovascular risk matters, but it is not enough by itself. A person with a high heart-attack risk and a high bleeding risk may still be a poor candidate. A clinician may consider age, smoking, blood pressure, cholesterol, diabetes, kidney disease, family history, coronary calcium, prior bleeding, medications, and patient preferences.

Some research is exploring whether subgroups such as people with high lipoprotein(a) or substantial coronary artery calcium might have a more favorable balance, but these are not universal indications to self-start aspirin. If your concern is high cholesterol or atherosclerosis risk, treatment with statins or other lipid-lowering therapy often has a clearer benefit-to-risk profile than aspirin. For context, see ApoB testing and heart risk.

People with diabetes deserve individualized discussion. Diabetes raises cardiovascular risk, but randomized trials and meta-analyses still show the same core tradeoff: modest prevention of vascular events versus more major bleeding. Diabetes alone does not mean every adult should take aspirin.

Who should usually not start aspirin

The USPSTF recommends against initiating low-dose aspirin for primary prevention in adults age 60 or older. This does not mean everyone already taking aspirin at 60 should abruptly stop; the original reason for therapy and the person’s risk profile still matter.

Aspirin is also generally a poor choice for primary prevention when bleeding risk is elevated. Examples include:

  • Active gastrointestinal bleeding or a recent significant bleed.
  • A history of intracranial hemorrhage.
  • A bleeding disorder or very low platelet count.
  • Peptic ulcer disease with substantial bleeding risk.
  • Concurrent use of medicines that significantly increase bleeding risk.
  • Uncontrolled severe hypertension, which can increase hemorrhagic complications.
  • Aspirin allergy or aspirin-exacerbated respiratory disease.

Age itself increases bleeding risk, which is one reason routine primary-prevention aspirin becomes less attractive in older adults.

Aspirin is not a substitute for blood-pressure or cholesterol treatment. If someone has a 10-year risk above 10% because of high LDL, smoking, or uncontrolled blood pressure, treating those causes directly often creates more benefit without the same bleeding tradeoff. The best prevention plan usually starts with smoking cessation, lipid management, blood-pressure control, physical activity, diabetes care, and a heart-healthy diet.

If you are taking aspirin “because my parents did,” or because it was recommended years ago before newer guidance, that is a reason to review it—not a reason to stop on your own.

Bleeding risk and drug interactions

Aspirin can cause bleeding anywhere, but gastrointestinal bleeding is the most common major concern. It can also increase intracranial hemorrhage risk. Updated meta-analyses of primary prevention trials consistently find fewer major cardiovascular events with aspirin but more major bleeding.

Risk rises when aspirin is combined with other drugs that affect clotting or irritate the gastrointestinal tract. Important examples include anticoagulants such as apixaban, rivaroxaban, dabigatran, or warfarin; other antiplatelet drugs such as clopidogrel; and nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen.

Do not assume that spacing these drugs by a few hours eliminates bleeding risk. Timing may affect specific interactions, but concurrent exposure over days or weeks still matters.

Selective serotonin reuptake inhibitors and some other antidepressants can modestly increase bleeding risk, especially when combined with antiplatelet drugs. Corticosteroids, heavy alcohol use, and a history of ulcer disease can also matter.

A proton-pump inhibitor may be prescribed to reduce upper gastrointestinal bleeding risk in selected patients, but it does not erase all bleeding risk and should not be used as a reason to take unnecessary aspirin.

Watch for black tarry stools, vomiting blood or material that looks like coffee grounds, unexplained weakness, persistent abdominal pain, or signs of anemia. Sudden severe headache, neurologic weakness, or confusion can indicate intracranial bleeding and requires emergency care.

Aspirin after a heart attack, stent, or stroke

Secondary prevention is different. Current coronary-disease guidelines continue to support antiplatelet therapy for many people with established coronary disease. After an acute coronary syndrome or coronary stent, aspirin is often combined temporarily with another antiplatelet drug, a strategy called dual antiplatelet therapy. The exact duration depends on the type of event or procedure, bleeding risk, and other medications.

People with a previous ischemic stroke or transient ischemic attack may also be prescribed antiplatelet therapy, but treatment depends on the stroke mechanism. If the stroke was caused by atrial fibrillation, an anticoagulant is usually more important than aspirin. Aspirin should not be viewed as an interchangeable “blood thinner.”

If you have established coronary disease and were told to take aspirin, do not stop it abruptly without discussing the plan with the prescribing clinician. After a recent coronary stent in particular, stopping antiplatelet therapy too early can raise the risk of stent thrombosis, a potentially fatal event.

The exact long-term regimen is increasingly individualized. Some patients remain on aspirin, some transition to another antiplatelet agent, and some who also require anticoagulation use different combinations to limit bleeding. The right answer depends on the reason for treatment.

Dose, timing, and common mistakes

When aspirin is used for prevention, “low dose” in the United States commonly means 81 mg daily. Other countries often use doses around 75–100 mg. Higher chronic doses generally increase bleeding without improving routine preventive benefit.

Enteric-coated aspirin may reduce stomach irritation for some people, but it does not reliably prevent serious gastrointestinal bleeding. The bleeding effect comes from platelet inhibition throughout the body, not only direct contact with the stomach lining.

Timing—morning versus evening—is much less important than taking the prescribed dose consistently. Do not double a dose after a missed tablet unless your clinician or pharmacist specifically advises it.

Common mistakes include:

  • Starting aspirin after seeing a high cholesterol result without assessing bleeding risk.
  • Using aspirin instead of calling emergency services during possible heart-attack symptoms.
  • Assuming “baby aspirin” is harmless because the dose is small.
  • Taking aspirin plus ibuprofen or naproxen regularly without discussing interactions.
  • Stopping aspirin after a stent because of bruising without contacting the cardiology team.
  • Taking aspirin for AFib stroke prevention when an anticoagulant is actually indicated.

Aspirin has a role in emergency heart-attack care for selected people, but emergency instructions depend on allergy, bleeding, and the clinical situation. If you think you are having a heart attack, call emergency services first rather than self-treating and waiting.

How to decide with your clinician

A useful decision is based on absolute benefit versus absolute harm. A 10% relative reduction in cardiovascular events means something very different when baseline risk is 2% versus 20%.

Ask these questions:

  • Am I using aspirin for primary or secondary prevention?
  • What is my estimated 10-year cardiovascular risk?
  • What factors increase my bleeding risk?
  • Would treating LDL, blood pressure, smoking, or diabetes produce more benefit?
  • Do I take another antiplatelet or anticoagulant?
  • If I am already taking aspirin, is there still a clear indication?

If prevention is the goal, focus first on interventions with strong net benefit. That includes controlling high blood pressure, treating elevated LDL when indicated, exercising regularly, avoiding tobacco, sleeping adequately, and eating a pattern rich in vegetables, fruits, whole grains, legumes, nuts, and unsaturated fats. For a broader overview, heart-healthy foods for cholesterol and blood pressure can help translate that into meals.

Aspirin is neither a vitamin nor a universal insurance policy. It is a medication with real benefits in the right patient and real harms in the wrong one. The best choice comes from knowing why you are taking it.

The benefit-versus-harm calculation becomes clearer when you think in absolute numbers. In a person with very low cardiovascular risk, aspirin may prevent very few events because there were not many expected events to prevent in the first place. The bleeding risk, however, does not fall to zero. In a person with established coronary disease, the baseline risk of another event is much higher, so the same antiplatelet effect can produce a larger absolute benefit.

This is why age-based rules should not be applied without context. A 62-year-old who has never had cardiovascular disease is different from a 62-year-old who had a heart attack last year. The first person may be advised not to start aspirin for primary prevention; the second may have a strong secondary-prevention indication.

Coronary artery calcium scoring sometimes enters the discussion for primary prevention. A high calcium score can identify a greater burden of subclinical atherosclerosis, and observational analyses suggest that selected people with substantial calcium and low bleeding risk may derive more benefit from aspirin. However, this is a nuanced decision, not a reason to buy aspirin after seeing a scan result. Statin therapy, blood-pressure control, and smoking cessation remain foundational.

Bleeding risk can also change over time. A person who tolerated aspirin for years may later develop an ulcer, start an anticoagulant, develop kidney disease, or become frailer and more prone to falls. Medication lists should therefore be reviewed periodically rather than assuming a preventive drug remains appropriate forever.

Before surgery or dental procedures, do not stop aspirin automatically. Whether it should be continued depends on the procedure and the reason for aspirin. In someone with a recent coronary stent, stopping antiplatelet therapy can be more dangerous than continuing it. The surgeon, dentist, and prescribing clinician may need to coordinate the plan.

Aspirin allergy requires special care. Some people develop hives or anaphylaxis; others with asthma and nasal polyps can have aspirin-exacerbated respiratory disease. Desensitization is possible in selected patients who have a strong cardiovascular indication, but that is a specialist-supervised process.

Pregnancy introduces a separate use case. Low-dose aspirin is sometimes prescribed to reduce the risk of preeclampsia in people with specific obstetric risk factors. That is not the same as cardiovascular primary prevention, and recommendations come from obstetric guidance. Pregnant people should follow their prenatal clinician’s instructions rather than applying adult heart-prevention rules to themselves.

Another misconception is that aspirin can “thin plaque” or lower cholesterol. It does neither. Aspirin changes platelet function. Statins and other lipid-lowering drugs target the atherosclerotic process more directly by lowering atherogenic lipoproteins and reducing future event risk.

If you bruise easily on aspirin, mention it at follow-up, but do not use bruising alone to decide whether to stop. Minor bruising is common; serious bleeding signs include black stool, vomiting blood, prolonged bleeding, unusual weakness, or neurologic symptoms. The response depends on severity and indication.

The safest preventive question is therefore not “Should everyone over a certain age take aspirin?” It is “What is my cardiovascular risk, what is my bleeding risk, and do I already have a condition for which antiplatelet therapy has proven benefit?”

Aspirin decisions should also be revisited after major health changes. New anemia, a gastrointestinal ulcer, a fall with head injury, kidney disease, initiation of an anticoagulant, or a new coronary event can all change the balance. Bring every over-the-counter pain reliever to the medication review, because people often forget that aspirin, ibuprofen, and naproxen can overlap in ways that increase bleeding or interfere with therapy.

If you need occasional pain relief while taking preventive aspirin, ask a pharmacist or clinician which option is safest for your conditions and other medicines. “Over the counter” does not mean interaction-free.

The decision should also reflect personal values. Some people place a very high priority on avoiding even a small chance of gastrointestinal bleeding; others with substantial cardiovascular risk may accept that tradeoff for a modest reduction in heart attack or ischemic stroke. Shared decision-making means translating percentages into understandable absolute risks and then matching the choice to the patient’s priorities. It does not mean that every option is equally appropriate. When the expected net benefit is negative—such as routine initiation in many older adults—guidelines advise against starting aspirin.
If you are uncertain why aspirin is on your medication list, ask the prescriber to state the indication plainly and document when the decision should be reviewed again.

References

Disclaimer

This article is general information, not a recommendation to start or stop aspirin. If you already take aspirin for a prior heart attack, stroke, coronary stent, or diagnosed vascular disease, do not discontinue it without guidance from the clinician managing that condition.